TABLE 2

Median (IQR) Monthly Use of Selected ASP-Targeted Antimicrobial Agents in DOTs/1000 PDs

Antibiotic NameBefore ASP, 2010 and 2011After ASP, 2014 and 2015Absolute ChangeP
Antibiotics audited by pediatric ASP
 Cefepime52.1 (34.9–57.7)45.6 (37.1–57.6)↓6.5.770
 Ceftazidimea4.0 (0.2–6.0)0.0 (0.0–2.7)↓4.0.006
 Ciprofloxacin7.5 (4.5–13.1)10.3 (5.4–14.7)↑2.8.321
 Clindamycin18.9 (16.1–27.8)17.0 (12.8–27.4)↓1.9.284
 Levofloxacin2.2 (0.0–6.9)1.3 (0.0–3.8)↓0.9.221
 Meropenem14.1 (2.9–23.5)17.9 (11.0–30.1)↑3.8.180
 Piperacillin-tazobactama43.8 (35.6–56.2)21.7 (27.1–44.9)↓22.1.034
 Rifampin4.3 (1.7–8.1)3.2 (0.15–9.5)↓1.0.649
 Tobramycina3.1 (1.1–6.2)0.0 (0.0–2.4)↓3.1.001
 Vancomycin IVa119.6 (103.1–134.9)99.7 (89.0–117.7)↓19.9.015
 Linezolida0.0 (0.0–1.9)3.4 (0.8–6.7)↑3.4.005
 Micafungina0.0 (0.0–0.0)8.4 (0.15–18.9)↑8.4.0005
 Liposomal amphotericina7.6 (4.3–15.2)2.7 (0.0–6.5)↓5.1.002
Commonly used non-ASP-targeted antibiotics
 Ampicillin124.3 (102.0–132.9)105.6 (92.6–120.4)↓18.7.076
 Ampicillin sulbactam14.5 (7.2–23.2)21.2 (12.5–26.5)↑6.7.091
 Nafcillin and oxacillin combineda8.6 (6.3–14.1)6.3 (2.7–7.3)↓2.3.016
 Cefoxitina0.0 (0.0–1.3)3.1 (2.3–7.0)↑3.1.001
 Cefotaxime48.1 (37.6–58.4)40 (29.0–48.8)↓8.1.266
 Ceftriaxonea28.7 (25.3–41.2)42.8 (38.9–51.3)↑14.1.001
 Trimethoprim-sulfamethoxazole15.6 (11.1–20.3)15.6 (13.5–22.8)0.433
 Gentamicina87.4 (71.0–97.7)65.5 (56.1–81.6)↓21.9.001
 Fluconazole15.9 (10.6–32.4)17.1 (12.5–24.3)↑1.2.837
  • a Significant change in antimicrobial use since initiation of pediatric ASP.